CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...

Jefferies analyst Akash Tewari maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $42.00. Akash Tewari’s rating is based on a combination of factors ...

Q4 2024 Earnings Call Transcript February 11, 2025 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.48 EPS, ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Citi raised the firm’s price target on Exelixis (EXEL) to $45 from $38 and keeps a Buy rating on the shares following the Q4 report. The ...

Exelixis Inc (EXEL) reports robust financial performance and outlines ambitious goals for its oncology portfolio amid market ...

Harry Wilson returns with his advice for all seven races at Newbury on Saturday – and the three live on ITV4 from Warwick . .

Exelixis has made significant strides in establishing itself as a multi-compound, multi-franchise oncology business.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

Djelo (FR) 5-4fav (11-10) Handy on outer, raced in 4th after 3rd, closed up after 7th, tracked leader 11th, outpaced by winner before 3 out, soon well beaten and plugged on same pace, 2nd of 6 ...

Objectives: To analyzed the clinical characteristics and treatment modalities of heat stroke (HS) and to identify risk factors for a poor prognosis of HS and provide reference suggestions for its ...